Product image of Mitomicina Medac (Mitomycin) supplied by GNH India

Mitomicina Medac

Active Ingredient:
Mitomycin
Origin:
EU

Mitomicina Medac (Mitomycin)

Mitomycin, the active ingredient in Mitomicina Medac, is an alkylating agent presented as a sterile solution for intravenous and intravesical use. It is employed in the treatment of certain solid tumours, including bladder cancer and gastrointestinal malignancies, by interfering with DNA replication in rapidly dividing cancer cells.

GNH India supplies Mitomicina Medac as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution.

Manufacturer / TM Owner

Medac Gesellschaft Für Klinische Spezialpräparate Mbh (Wedel)

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mitomycin is used as an antineoplastic alkylating agent in several solid tumour indications.

  • Bladder cancer (intravesical): reduces tumour recurrence after transurethral resection.
  • Gastric cancer (systemic): incorporated into combination regimens to improve response rates.
  • Pancreatic cancer (systemic): part of multi‑drug chemotherapy protocols aimed at extending survival.

How It Works

  • Mitomycin acts as a DNA cross‑linking agent that forms covalent bonds between adjacent DNA strands. This cross‑linking blocks DNA replication and transcription, leading to inhibition of cell division and ultimately causing apoptosis of rapidly proliferating cancer cells.

Side Effects

Adverse reactions may vary with dose, route of administration and patient factors.

Common Side Effects

  • Nausea: mild to moderate gastrointestinal upset.
  • Vomiting: occasional emesis following infusion.
  • Myelosuppression: reduced white blood cell and platelet counts.
  • Anemia: decreased hemoglobin levels causing fatigue.
  • Fatigue: generalized weakness during treatment.
  • Alopecia: temporary hair loss.

Serious or Rare Side Effects

  • Severe bone marrow suppression: can lead to life‑threatening infections.
  • Pulmonary toxicity: interstitial pneumonitis or fibrosis.
  • Hemolytic‑uremic syndrome: acute renal failure with hemolysis.
  • Severe allergic reactions: anaphylaxis or serum sickness.
  • Renal toxicity: impaired kidney function.
  • Secondary malignancies: rare development of new cancers.

Precautions & Warnings

Mitomicina Medac requires careful monitoring and patient assessment before and during therapy.

  • Monitor blood counts: perform regular CBC to detect myelosuppression.
  • Assess renal function: evaluate creatinine and clearance prior to dosing.
  • Evaluate pulmonary status: baseline lung function tests are recommended.
  • Avoid use in patients with known hypersensitivity to mitomycin or related compounds.
  • Use effective contraception: both male and female patients should employ reliable birth control during treatment and for a defined period after.
  • Store at controlled room temperature: keep in original container, protect from light and moisture.

Avoid Interactions

Mitomycin may interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid)

  • High‑dose cyclophosphamide: additive bone‑marrow toxicity.
  • Warfarin: increased risk of bleeding.
  • Live vaccines: risk of uncontrolled infection.

Moderate Interactions (Monitor Closely)

  • Nephrotoxic agents (e.g., aminoglycosides): monitor renal parameters.
  • Other myelosuppressive chemotherapy: adjust dosing and monitor blood counts.
  • CYP450 inducers or inhibitors: may affect mitomycin metabolism, requiring dose adjustment.

Frequently Asked Questions

Mitomicina Medac contains mitomycin, an alkylating antineoplastic agent used primarily for the treatment of certain solid tumours such as bladder cancer (administered intravesically) and gastrointestinal cancers when given intravenously.

Mitomycin functions as a DNA cross‑linking agent. It creates covalent bonds between DNA strands, preventing replication and transcription, which leads to cell cycle arrest and apoptosis of rapidly dividing cancer cells.

The specific dose and schedule of Mitomicina Medac are determined by the prescribing physician based on the indication, patient condition, and treatment protocol. Dosing is individualized and not standardized in public information.

Mitomycin is classified as contraindicated in pregnancy because of its potential teratogenic effects. It is also not recommended during breastfeeding, as it may be excreted in milk and harm the infant. Consultation with a healthcare professional is essential.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Mitomycin differs from many alkylating agents by its ability to form DNA cross‑links rather than simple alkylation. This results in a distinct toxicity profile, including notable pulmonary and renal risks, whereas agents like cyclophosphamide may have more pronounced hemorrhagic cystitis. Choice of therapy depends on tumour type and patient factors.

Mitomicina Medac should be stored at controlled room temperature, below 25 °C, in its original packaging. Protect the solution from light, moisture and extreme temperature fluctuations. Follow aseptic handling procedures during preparation and administration.

The product is supplied as a sterile solution for intravenous infusion or intravesical instillation. Administration is performed by qualified healthcare professionals in a clinical setting, following aseptic technique and appropriate infusion rates as directed by the prescriber.

Serious risks include severe bone‑marrow suppression leading to infections, pulmonary toxicity such as interstitial pneumonitis, renal failure, hemolytic‑uremic syndrome, and rare secondary malignancies. Patients should be closely monitored for these events throughout therapy.

Mitomicina Medac is contraindicated in patients with known hypersensitivity to mitomycin, those with severe bone‑marrow failure, uncontrolled infections, or significant renal or pulmonary impairment. It should also be avoided in pregnant women and breastfeeding mothers.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Mitomycin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT